GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals analyst meets
51 filed, newest first. Page 1 of 2.
Oct 2026
28 Oct · Analysts
Aug 2026
5 Aug · Analysts
Jul 2026
21 Jul · Analysts
May 2026
18 May · Analysts
7 May · Analysts
Feb 2026
11 Feb · Analysts
3 Feb · Analysts
Nov 2025
10 Nov · Analysts
Oct 2025
30 Oct · Analysts
Aug 2025
8 Aug · Analysts
2 Aug · Analysts
Jul 2025
28 Jul · Analysts
May 2025
15 May · Analysts
8 May · Analysts
Feb 2025
11 Feb · Analysts
Oct 2024
24 Oct · Analysts
Jul 2024
31 Jul · Analysts
May 2024
10 May · Analysts
Feb 2024
12 Feb · Analysts
Nov 2023
23 Nov · Analysts
20 Nov · Analysts
Aug 2023
11 Aug · Analysts
Jun 2023
27 Jun · Analysts
8 Jun · Analysts
Mar 2023
13 Mar · Analysts
Aug 2022
22 Aug · Analysts
Nov 2021
15 Nov · Analysts
Aug 2021
18 Aug · Analysts
11 Aug · Analysts
Sep 2020
18 Sep · Analysts
Feb 2020
4 Feb · Analysts
4 Feb · Analysts
Nov 2019
6 Nov · Analysts
Oct 2019
30 Oct · Analysts
Sep 2019
5 Sep · Analysts
Aug 2019
12 Aug · Analysts
1 Aug · Analysts
Feb 2019
21 Feb · Analysts
14 Feb · Analysts
1 Feb · Analysts
Jan 2019
25 Jan · Analysts
Aug 2018
30 Aug · Analysts
Jun 2018
1 Jun · Analysts
Mar 2018
16 Mar · Analysts
1 Mar · Analysts
Sep 2017
1 Sep · Analysts
Aug 2017
18 Aug · Analysts
Jun 2017
1 Jun · Analysts
Sep 2016
12 Sep · Analysts